- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 24, 2023
Finance
May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M
Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more
BioCentury | Feb 7, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into cancer
BioCentury’s Distillery highlights white space cancer targets, new protein degraders and strategies to boost T cell responses to tumors
BioCentury | Aug 27, 2021
Distillery Therapeutics
Targeting PIN1 to improve immunochemotherapy for pancreatic cancer
BioCentury | Jun 6, 2020
Translation in Brief
Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more
BioCentury’s roundup of preclinical news
BioCentury | Oct 31, 2019
Company News
Backed by Morningside, Pinteon’s first clinical program targets toxic tau isoform
BioCentury | Aug 27, 2015
Distillery Therapeutics
Therapeutics: Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1)
Items per page:
1 - 10 of 24